| abstract |
"MOLECULAR ADJUVANT". The present disclosure refers to therapies for the treatment of disorders characterized by a disorder-associated antigen (DAA); vaccination methods are disclosed. In particular, the disclosure describes an ADC anti-CD25 molecular adjuvant for use in inducing or enhancing a subject's immune response against a DAA, allowing treatment of the disorder characterized by the DAA. Dosage regimens for treating solid tumors with an A are also disclosed. The present disclosure relates to the treatment of pathological conditions, such as cancer, with anti-CD25 ADCs. |